Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

Disc Medicine, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, JULY 31, 2026 (GLOBE NEWSWIRE) -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

DISC MEDICINE INVESTOR NEWS: IF YOU HAVE SUFFERED LOSSES IN DISC MEDICINE, INC. (NASDAQ: IRON), YOU ARE ENCOURAGED TO CONTACT THE ROSEN LAW FIRM ABOUT YOUR RIGHTS

WATERTOWN, MASS., JULY 30, 2026 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, AND PROVIDED A REVIEW OF RECENT PROGRAM AND CORPORATE DEVELOPMENTS.

DISC MEDICINE REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

NEW YORK, JULY 28, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC. SO WHAT: IF YOU PURCHASED DISC MEDICINE SECURITIES YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.

NEW YORK, JULY 22, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

NEW YORK, JULY 15, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

NEW YORK, JULY 11, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

NEW YORK, JULY 08, 2026 (GLOBE NEWSWIRE) -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

NEW YORK, JULY 05, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

NEW YORK, JULY 01, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

NEW YORK, JUNE 28, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

NEW YORK, JUNE 25, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

NEW YORK, JUNE 21, 2026 (GLOBE NEWSWIRE) -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

NEW YORK, JUNE 18, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

NEW YORK, JUNE 15, 2026 (GLOBE NEWSWIRE) -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

NEW YORK, JUNE 12, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

IRON INVESTOR NEWS: IF YOU HAVE SUFFERED LOSSES IN DISC MEDICINE, INC. (NASDAQ: IRON), YOU ARE ENCOURAGED TO CONTACT THE ROSEN LAW FIRM ABOUT YOUR RIGHTS

WATERTOWN, MASS., JUNE 12, 2026 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY ANNOUNCES UPDATED DATA FROM MULTIPLE CLINICAL PROGRAMS TO BE PRESENTED AT THE EHA ANNUAL MEETING IN STOCKHOLM, SWEDEN. DATA FROM THE RALLY-MF TRIAL OF DISC-0974 IN PATIENTS WITH MF AND ANEMIA, TO BE PRESENTED IN AN ORAL SESSION TODAY, DEMONSTRATE MEANINGFUL, DURABLE OVERALL ANEMIA RESPONSES ACROSS ALL PATIENT SUBGROUPS, REGARDLESS OF BASELINE TRANSFUSION STATUS OR CONCOMITANT JAK INHIBITOR USE. UPDATED DATA FROM THE HELIOS OPEN-LABEL EXTENSION TRIAL OF BITOPERTIN IN EPP, TO BE PRESENTED IN A POSTER SESSION TOMORROW, JUNE 13, SHOW SUSTAINED REDUCTIONS IN PPIX, SIGNIFICANT IMPROVEMENT IN LIGHT TOLERANCE MEASURES, AND FAVORABLE LONGER-TERM SAFETY IN PATIENTS TREATED WITH BITOPERTIN.

DISC MEDICINE PRESENTS POSITIVE CLINICAL UPDATES AT THE 2026 EUROPEAN HEMATOLOGY ASSOCIATION (EHA) ANNUAL MEETING

NEW YORK, JUNE 09, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

WATERTOWN, MASS., JUNE 09, 2026 (GLOBE NEWSWIRE) -- DISC MEDICINE, INC. (NASDAQ:IRON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NOVEL TREATMENTS FOR PATIENTS SUFFERING FROM SERIOUS HEMATOLOGIC DISEASES, TODAY ANNOUNCED IT HAS COMPLETED A TYPE A MEETING WITH THE US FOOD AND DRUG ADMINISTRATION (FDA) TO DISCUSS THE COMPLETE RESPONSE LETTER (CRL) TO THE NEW DRUG APPLICATION (NDA) FOR BITOPERTIN IN ERYTHROPOIETIC PROTOPORPHYRIA (EPP). IN THIS MEETING, DISC ALIGNED WITH THE FDA THAT THE ONGOING PHASE 3 APOLLO STUDY, IF SUCCESSFUL, CAN SERVE AS THE BASIS FOR A RESPONSE TO THE CRL AND COULD POTENTIALLY SUPPORT A TRADITIONAL APPROVAL.

DISC MEDICINE PROVIDES UPDATE FROM FDA TYPE A MEETING FOR BITOPERTIN IN ERYTHROPOIETIC PROTOPORPHYRIA

NEW YORK, JUNE 05, 2026 (GLOBE NEWSWIRE) -- WHY:ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF DISC MEDICINE, INC. (NASDAQ: IRON) RESULTING FROM ALLEGATIONS THAT DISC MEDICINE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.

Disc Medicine, Inc.

IRON

Price

Financial Reports

No items found.

Press Releases

Disc Medicine, Inc.

IRON.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

IRON